孤兒藥CDMO市場分析及至2035年預測：類型、產品、服務、技術、應用、製程、最終用戶、階段

全球孤兒藥CDMO市場預計將從2025年的148億美元成長到2035年的291億美元，CAGR為7.0%。孤兒藥CDMO市場持續擴張，主要得益於獲批孤兒藥數量的增加以及創新製藥公司外包業務的日益成長。根據美國食品藥物管理局（FDA）統計，每年有數百種孤兒藥被認定為孤兒藥，反映了罕見疾病治療藥物研發的持續進展。歐洲藥品管理局（EMA）也報告指出，歐洲的孤兒藥認定數量持續成長。產業預測，在生物製藥研發管線擴張、個人化醫療發展以及對專業化生產能力投資增加的推動下，全球孤兒藥CDMO市場規模將在2024年超過50億美元，並在2032年之前保持超過9%的CAGR。

孤兒藥CDMO市場的核心在於生產服務，包括製劑開發、分析和品管、法規支援、臨床試驗、供應鏈管理以及包裝解決方案。這些一體化服務使委託方能夠外包專業任務，同時保持產品品質並確保符合嚴格的監管標準。先進的製劑技術增強了生物製藥和小分子藥物的穩定性，而分析檢測則確保了批間一致性和產品安全性。法規方面的專業知識加速了孤兒藥在多個司法管轄區的批准。對靈活生產、更短的研發週期和更具成本效益的商業化方式每日成長的需求，持續推動外包合作關係的拓展，並帶動了長期服務需求的成長。

孤兒藥CDMO市場的技術進步主要由生物製程、冷凍乾燥、噴霧乾燥、微膠囊化、奈米顆粒工程和連續生產平台所驅動。生物製程提高了產量和可擴展性，支持複雜生物製藥的生產；凍乾增強了對溫度敏感的治療藥物的產品穩定性；噴霧乾燥和微囊化改善了藥物遞送和生物利用度；奈米顆粒工程則實現了針對罕見疾病的標靶治療。連續生產提高了營運效率，最大限度地減少了生產變異性，並減少了廢棄物。對先進製造技術的持續投資使CDMO能夠滿足不斷變化的監管要求和日益成長的精準醫療需求，支持市場的永續擴張。

區域概覽

北美憑藉其成熟的製藥生產基礎設施、發達的生物技術生態系統以及有利於孤兒藥發展的法規結構，佔據了孤兒藥CDMO市場最大的佔有率。在《孤兒藥法案》的獎勵、強而有力的智慧財產權保護和充足的研究經費的支持下，美國在全球孤兒藥研發中佔據了重要地位。該地區擁有眾多專業的CDMO，配備了先進的生物製藥生產技術、符合GMP標準的設施以及經驗豐富的法規遵循團隊。生物技術公司、學術機構和契約製造製造商之間的密切合作不斷提升產能，並鞏固了其市場主導地位。

在亞太地區，孤兒藥合約研發生產機構（CDMO）市場正顯著擴張，這得益於對製藥生產基礎設施投資的增加、生物技術能力的提升以及政府的支持措施。中國、印度、韓國和新加坡等國家不斷加強其先進的生物製藥生產和法律規範，同時吸引跨國公司的外包合約。生產成本的降低、熟練科學專家的湧入以及先進製造技術的日益普及，正推動著製藥公司全球供應鏈的多元化發展。隨著產能擴張計畫、技術轉移和臨床開發活動的增加，預計該地區的孤兒藥生產服務將實現持續的長期成長。

主要趨勢和促進因素

精密製造重塑孤兒藥研發的未來。

先進生物製藥製造技術與個人化醫療生產的融合變革孤兒藥CDMO市場。契約製造生產商拓展其在細胞和基因治療生產、高活性原料藥、無菌填充和包裝過程以及數位化製造技術方面的能力。自動化、人工智慧（AI）製程最佳化和持續品質監控的日益普及，在提高生產效率的同時，也確保了合規性。生技創新者與專業CDMO之間的策略合作日益普遍，目的是加速複雜罕見疾病療法的商業化進程。

罕見疾病藥物研發管線的擴展加速CDMO外包的需求。

罕見病患疾病率和診斷數量的不斷上升，以及孤兒藥開發平臺的不斷擴展，顯著推動了對專業CDMO服務的需求。製藥和生物技術公司擴大將研發和生產外包，以利用先進技術、專業的監管知識和靈活的生產能力，而無需投入大量資本。有利的監管激勵措施、加快的核准流程以及對生物製藥和精準醫療領域投資的增加，進一步刺激了外包活動，並支持孤兒藥CDMO市場的持續成長。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機會
• 市場限制因素
• 年複合成長率分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 低分子化合物
  • 生物製藥
  • 基因治療
  • 細胞療法
  • 其他
• 市場規模及預測：依產品分類
  • 活性藥物成分（API）
  • 最終配方（FDF）
  • 中間體
  • 其他
• 市場規模及預測：依服務分類
  • 製造業
  • 分析服務
  • 監理合規支持
  • 包裝
  • 其他
• 市場規模及預測：依技術分類
  • 生物程序
  • 冷凍乾燥
  • 噴霧乾燥
  • 微膠囊化
  • 其他
• 市場規模及預測：依應用領域分類
  • 腫瘤學
  • 神經病學
  • 血液學
  • 代謝性疾病
  • 感染疾病
  • 其他
• 市場規模及預測：依製程分類
  • 用於臨床試驗的生產
  • 商業生產
  • 其他
• 市場規模及預測：依最終用戶分類
  • 製藥公司
  • 生技公司
  • 研究機構
  • 其他
• 市場規模及預測：依階段分類
  • 臨床前
  • 臨床
  • 商業生產
  • 其他

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲國家
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 其他亞太國家
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲國家
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲國家

第6章 市場策略

• 供需差距分析
• 貿易和物流限制
• 定價和成本利潤率趨勢
• 市場滲透率
• 消費者分析
• 監管概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要公司的策略

第8章 公司簡介

• Lonza
• Catalent
• Thermo Fisher Scientific
• Samsung Biologics
• WuXi AppTec
• Boehringer Ingelheim
• Recipharm
• Siegfried Holding
• Piramal Pharma Solutions
• Fujifilm Diosynth BIoTechnologies
• AGC Biologics
• Charles River Laboratories
• Almac Group
• Cambrex
• Patheon
• Vetter Pharma
• Baxter BioPharma Solutions
• Ajinomoto Bio-Pharma Services
• Rentschler Biopharma
• CordenPharma

第9章 關於我們

The global Orphan Drugs CDMO Market is projected to grow from $14.8 billion in 2025 to $29.1 billion by 2035, at a compound annual growth rate (CAGR) of 7.0%. The orphan drugs CDMO market continues to expand alongside rising orphan drug approvals and increasing outsourcing activities by pharmaceutical innovators. According to the U.S. Food and Drug Administration (FDA), hundreds of orphan drug designations are granted annually, reflecting sustained development activity for rare disease therapies. The European Medicines Agency (EMA) also reports continuous growth in orphan medicinal product designations across Europe. Industry estimates indicate the global orphan drugs CDMO market exceeded USD 5 billion in 2024 and is projected to register a CAGR exceeding 9% through 2032, supported by expanding biologics pipelines, personalized medicine development, and increasing investment in specialized manufacturing capabilities.

Manufacturing services constitute the core of the orphan drugs CDMO market, supported by formulation development, analytical and quality control, regulatory support, clinical trials, supply chain management, and packaging solutions. These integrated services enable sponsors to outsource specialized activities while maintaining product quality and compliance with stringent regulatory standards. Advanced formulation capabilities improve stability for biologics and small molecules, whereas analytical testing ensures batch consistency and product safety. Regulatory expertise accelerates orphan drug approvals across multiple jurisdictions. Growing demand for flexible manufacturing, reduced development timelines, and cost-efficient commercialization continues to expand outsourcing partnerships, reinforcing long-term service demand.

Technology adoption in the orphan drugs CDMO market is driven by bioprocessing, lyophilization, spray drying, microencapsulation, nanoparticle engineering, and continuous manufacturing platforms. Bioprocessing supports complex biologics production with enhanced yield and scalability, while lyophilization improves product stability for temperature-sensitive therapeutics. Spray drying and microencapsulation enhance drug delivery and bioavailability, whereas nanoparticle engineering enables targeted therapies for rare diseases. Continuous manufacturing increases operational efficiency, minimizes production variability, and reduces waste. Continuous investment in advanced manufacturing technologies enables CDMOs to meet evolving regulatory expectations and growing demand for precision medicines, supporting sustainable market expansion.

Geographical Overview

North America represents the largest share of the orphan drugs CDMO market due to its mature pharmaceutical manufacturing infrastructure, extensive biotechnology ecosystem, and favorable orphan drug regulatory framework. The United States accounts for a significant proportion of global orphan drug development, supported by incentives under the Orphan Drug Act, strong intellectual property protection, and substantial research funding. The region hosts numerous specialized CDMOs equipped with advanced biologics manufacturing technologies, GMP-certified facilities, and experienced regulatory teams. Strong collaboration between biotechnology companies, academic institutions, and contract manufacturers continues to strengthen production capacity and sustain market leadership.

Asia-Pacific is witnessing substantial expansion in the orphan drugs CDMO market through increasing investments in pharmaceutical manufacturing infrastructure, expanding biotechnology capabilities, and supportive government initiatives. Countries including China, India, South Korea, and Singapore continue to strengthen advanced biologics manufacturing and regulatory frameworks while attracting multinational outsourcing contracts. Lower production costs, availability of skilled scientific professionals, and growing adoption of advanced manufacturing technologies encourage pharmaceutical companies to diversify global supply chains. Capacity expansion projects, technology transfers, and increasing clinical development activities position the region for sustained long-term growth in orphan drug manufacturing services.

Key Trends and Drivers

Precision Manufacturing Reshapes the Future of Orphan Drug Development:

The integration of advanced biologics manufacturing with personalized medicine production is transforming the orphan drugs CDMO market. Contract manufacturers are expanding capabilities in cell and gene therapy production, high-potency APIs, sterile fill-finish operations, and digital manufacturing technologies. Increased adoption of automation, artificial intelligence-driven process optimization, and continuous quality monitoring improves manufacturing efficiency while supporting regulatory compliance. Strategic partnerships between biotechnology innovators and specialized CDMOs are becoming increasingly common to accelerate commercialization of complex orphan therapies.

Expanding Rare Disease Pipeline Accelerates CDMO Outsourcing Demand:

Growing prevalence and diagnosis of rare diseases, combined with expanding orphan drug development pipelines, are significantly driving demand for specialized CDMO services. Pharmaceutical and biotechnology companies increasingly outsource development and manufacturing to access advanced technologies, specialized regulatory expertise, and flexible production capacity without substantial capital investment. Favorable regulatory incentives, accelerated approval pathways, and increasing investment in biologics and precision medicine further stimulate outsourcing activities, supporting sustained expansion of the orphan drugs CDMO market.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Small Molecules
  • 4.1.2 Biologics
  • 4.1.3 Gene Therapies
  • 4.1.4 Cell Therapies
  • 4.1.5 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Active Pharmaceutical Ingredients (APIs)
  • 4.2.2 Finished Dosage Forms (FDFs)
  • 4.2.3 Intermediates
  • 4.2.4 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Manufacturing
  • 4.3.2 Analytical Services
  • 4.3.3 Regulatory Support
  • 4.3.4 Packaging
  • 4.3.5 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Bioprocessing
  • 4.4.2 Lyophilization
  • 4.4.3 Spray Drying
  • 4.4.4 Microencapsulation
  • 4.4.5 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Neurology
  • 4.5.3 Hematology
  • 4.5.4 Metabolic Disorders
  • 4.5.5 Infectious Diseases
  • 4.5.6 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Clinical Trial Manufacturing
  • 4.6.2 Commercial Manufacturing
  • 4.6.3 Others
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Pharmaceutical Companies
  • 4.7.2 Biotechnology Companies
  • 4.7.3 Research Institutes
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Stage (2020-2035)
  • 4.8.1 Preclinical
  • 4.8.2 Clinical
  • 4.8.3 Commercial
  • 4.8.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 Process
    • 5.2.1.7 End User
    • 5.2.1.8 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 Process
    • 5.2.2.7 End User
    • 5.2.2.8 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 Process
    • 5.2.3.7 End User
    • 5.2.3.8 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 Process
    • 5.3.1.7 End User
    • 5.3.1.8 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 Process
    • 5.3.2.7 End User
    • 5.3.2.8 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 Process
    • 5.3.3.7 End User
    • 5.3.3.8 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 Process
    • 5.4.1.7 End User
    • 5.4.1.8 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 Process
    • 5.4.2.7 End User
    • 5.4.2.8 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 Process
    • 5.4.3.7 End User
    • 5.4.3.8 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 Process
    • 5.4.4.7 End User
    • 5.4.4.8 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 Process
    • 5.4.5.7 End User
    • 5.4.5.8 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 Process
    • 5.4.6.7 End User
    • 5.4.6.8 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 Process
    • 5.4.7.7 End User
    • 5.4.7.8 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 Process
    • 5.5.1.7 End User
    • 5.5.1.8 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 Process
    • 5.5.2.7 End User
    • 5.5.2.8 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 Process
    • 5.5.3.7 End User
    • 5.5.3.8 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 Process
    • 5.5.4.7 End User
    • 5.5.4.8 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 Process
    • 5.5.5.7 End User
    • 5.5.5.8 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 Process
    • 5.5.6.7 End User
    • 5.5.6.8 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 Process
    • 5.6.1.7 End User
    • 5.6.1.8 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 Process
    • 5.6.2.7 End User
    • 5.6.2.8 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 Process
    • 5.6.3.7 End User
    • 5.6.3.8 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 Process
    • 5.6.4.7 End User
    • 5.6.4.8 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 Process
    • 5.6.5.7 End User
    • 5.6.5.8 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Lonza
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Catalent
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Thermo Fisher Scientific
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Samsung Biologics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 WuXi AppTec
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Boehringer Ingelheim
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Recipharm
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Siegfried Holding
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Piramal Pharma Solutions
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Fujifilm Diosynth Biotechnologies
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 AGC Biologics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Charles River Laboratories
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Almac Group
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Cambrex
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Patheon
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Vetter Pharma
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Baxter BioPharma Solutions
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Ajinomoto Bio-Pharma Services
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Rentschler Biopharma
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 CordenPharma
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us